Cargando…

Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations

Keeping the potential synergy of biological activity of synthetic anomalous derivatives of deazapurines and l-ascorbic acid (l-AA) in mind, we have synthesized new 3-, 7- and 9-deazapurine derivatives of l-ascorbic (1–4, 8–10, 13–15) and imino-l-ascorbic acid (5–7, 11, 12, 16–19). These novel compou...

Descripción completa

Detalles Bibliográficos
Autores principales: Stipković Babić, Maja, Makuc, Damjan, Plavec, Janez, Martinović, Tamara, Kraljević Pavelić, Sandra, Pavelić, Krešimir, Snoeck, Robert, Andrei, Graciela, Schols, Dominique, Wittine, Karlo, Mintas, Mladen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125971/
https://www.ncbi.nlm.nih.gov/pubmed/26291038
http://dx.doi.org/10.1016/j.ejmech.2015.08.008
_version_ 1783516058483687424
author Stipković Babić, Maja
Makuc, Damjan
Plavec, Janez
Martinović, Tamara
Kraljević Pavelić, Sandra
Pavelić, Krešimir
Snoeck, Robert
Andrei, Graciela
Schols, Dominique
Wittine, Karlo
Mintas, Mladen
author_facet Stipković Babić, Maja
Makuc, Damjan
Plavec, Janez
Martinović, Tamara
Kraljević Pavelić, Sandra
Pavelić, Krešimir
Snoeck, Robert
Andrei, Graciela
Schols, Dominique
Wittine, Karlo
Mintas, Mladen
author_sort Stipković Babić, Maja
collection PubMed
description Keeping the potential synergy of biological activity of synthetic anomalous derivatives of deazapurines and l-ascorbic acid (l-AA) in mind, we have synthesized new 3-, 7- and 9-deazapurine derivatives of l-ascorbic (1–4, 8–10, 13–15) and imino-l-ascorbic acid (5–7, 11, 12, 16–19). These novel compounds were evaluated for their cytostatic and antiviral activity in vitro against a panel of human malignant tumour cell lines and normal murine fibroblasts (3T3). Among all evaluated compounds, the 9-deazapurine derivative of l-AA (13) exerted the most potent inhibitory activity on the growth of CEM/0 cells (IC(50) = 4.1 ± 1.8 μM) and strong antiproliferative effect against L1210/0 (IC(50) = 4.7 ± 0.1 μM) while the 9-deazahypoxanthine derivative of l-AA (15) showed the best effect against HeLa cells (IC(50) = 5.6 ± 1.3 μM) and prominent effect on L1210/0 (IC(50) = 4.5 ± 0.5 μM). Furthermore, the 9-deazapurine derivative disubstituted with two imino-l-AA moieties (18) showed the best activity against L1210/0 tumour cells (IC(50) = 4.4 ± 0.3 μM) and the most pronounced antiproliferative effects against MiaPaCa-2 cells (IC(50) = 5.7 ± 0.2 μM). All these compounds showed selective cytostatic effect on tumour cell lines in comparison with embryonal murine fibroblasts (3T3). When evaluating their antiviral activity, the 3-deazapurine derivative of l-AA (3) exhibited the highest activity against both laboratory-adapted strains of human cytomegalovirus (HCMV) (AD-169 and Davis) with EC(50) values comparable to those of the well-known anti-HCMV drug ganciclovir and without cytotoxic effects on normal human embryonal lung (HEL) cells.
format Online
Article
Text
id pubmed-7125971
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-71259712020-04-08 Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations Stipković Babić, Maja Makuc, Damjan Plavec, Janez Martinović, Tamara Kraljević Pavelić, Sandra Pavelić, Krešimir Snoeck, Robert Andrei, Graciela Schols, Dominique Wittine, Karlo Mintas, Mladen Eur J Med Chem Research Paper Keeping the potential synergy of biological activity of synthetic anomalous derivatives of deazapurines and l-ascorbic acid (l-AA) in mind, we have synthesized new 3-, 7- and 9-deazapurine derivatives of l-ascorbic (1–4, 8–10, 13–15) and imino-l-ascorbic acid (5–7, 11, 12, 16–19). These novel compounds were evaluated for their cytostatic and antiviral activity in vitro against a panel of human malignant tumour cell lines and normal murine fibroblasts (3T3). Among all evaluated compounds, the 9-deazapurine derivative of l-AA (13) exerted the most potent inhibitory activity on the growth of CEM/0 cells (IC(50) = 4.1 ± 1.8 μM) and strong antiproliferative effect against L1210/0 (IC(50) = 4.7 ± 0.1 μM) while the 9-deazahypoxanthine derivative of l-AA (15) showed the best effect against HeLa cells (IC(50) = 5.6 ± 1.3 μM) and prominent effect on L1210/0 (IC(50) = 4.5 ± 0.5 μM). Furthermore, the 9-deazapurine derivative disubstituted with two imino-l-AA moieties (18) showed the best activity against L1210/0 tumour cells (IC(50) = 4.4 ± 0.3 μM) and the most pronounced antiproliferative effects against MiaPaCa-2 cells (IC(50) = 5.7 ± 0.2 μM). All these compounds showed selective cytostatic effect on tumour cell lines in comparison with embryonal murine fibroblasts (3T3). When evaluating their antiviral activity, the 3-deazapurine derivative of l-AA (3) exhibited the highest activity against both laboratory-adapted strains of human cytomegalovirus (HCMV) (AD-169 and Davis) with EC(50) values comparable to those of the well-known anti-HCMV drug ganciclovir and without cytotoxic effects on normal human embryonal lung (HEL) cells. Elsevier Masson SAS. 2015-09-18 2015-08-10 /pmc/articles/PMC7125971/ /pubmed/26291038 http://dx.doi.org/10.1016/j.ejmech.2015.08.008 Text en Copyright © 2015 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Paper
Stipković Babić, Maja
Makuc, Damjan
Plavec, Janez
Martinović, Tamara
Kraljević Pavelić, Sandra
Pavelić, Krešimir
Snoeck, Robert
Andrei, Graciela
Schols, Dominique
Wittine, Karlo
Mintas, Mladen
Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title_full Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title_fullStr Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title_full_unstemmed Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title_short Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations
title_sort novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: synthesis, antitumour and antiviral activity evaluations
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125971/
https://www.ncbi.nlm.nih.gov/pubmed/26291038
http://dx.doi.org/10.1016/j.ejmech.2015.08.008
work_keys_str_mv AT stipkovicbabicmaja novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT makucdamjan novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT plavecjanez novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT martinovictamara novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT kraljevicpavelicsandra novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT pavelickresimir novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT snoeckrobert novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT andreigraciela novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT scholsdominique novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT wittinekarlo novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations
AT mintasmladen novelhalogenated3deazapurine7deazapurineandalkylated9deazapurinederivativesoflascorbicoriminolascorbicacidsynthesisantitumourandantiviralactivityevaluations